クリニカルリサーチセンター

Medicine & Life Sciences

1. 1-(3-sulfonatopropyl)-4-(beta)(2-(di-n-butylamino)-6-naphthylvinyl)pyridinium betaine 17%
2. Acidosis 40%
3. Acute Kidney Injury 36%
4. Airway Obstruction 41%
5. Alleles 43%
6. Alveolar Epithelial Cells 43%
7. Alveolar Macrophages 69%
8. Antidepressive Agents 20%
9. Antihypertensive Agents 35%
10. Benzodiazepines 23%
11. Brain 22%
12. Brain Stem 34%
13. Bronchoalveolar Lavage Fluid 23%
14. Calciphylaxis 60%
15. candesartan 47%
16. Cardiovascular Diseases 30%
17. Case-Control Studies 31%
18. CC Chemokines 49%
19. Chemokine CXCL2 18%
20. Chronic Kidney Failure 34%
21. Chronic Obstructive Pulmonary Disease 68%
22. Citalopram 36%
23. Clinical Trials 18%
24. Clopidogrel 22%
25. Cohort Studies 26%
26. Costs and Cost Analysis 24%
27. Curcumin 44%
28. Cytochrome P-450 CYP2C19 51%
29. Cytochrome P-450 CYP2D6 48%
30. Cytokines 19%
31. Depression 72%
32. Desipramine 29%
33. Drug Industry 22%
34. Duodenum 39%
35. Emphysema 39%
36. ErbB Receptors 36%
37. Formal Social Control 19%
38. Granulocyte-Macrophage Colony-Stimulating Factor 40%
39. Hepatocyte Growth Factor 46%
40. Human Influenza 35%
41. Hypertension 27%
42. Hypnotics and Sedatives 29%
43. Imipramine 46%
44. Innate Immunity 22%
45. Interleukin-8 36%
46. Japan 100%
47. keratinocyte-derived chemokines 21%
48. Ligands 27%
49. Lipopolysaccharides 55%
50. Locus Coeruleus 69%
51. Logistic Models 20%
52. Lung 38%
53. Lung Injury 54%
54. Lung Neoplasms 40%
55. Macrophages 43%
56. Major Depressive Disorder 86%
57. Manufacturing Industry 30%
58. Meta-Analysis 28%
59. Microdialysis 43%
60. Neoplasm Metastasis 23%
61. Neoplasms 20%
62. NF-E2-Related Factor 2 55%
63. Nifedipine 21%
64. Nitrazepam 61%
65. Non-Smokers 21%
66. Paliperidone Palmitate 19%
67. Pancreatic Elastase 45%
68. Pemphigus 48%
69. Percutaneous Coronary Intervention 38%
70. Pharmaceutical Preparations 20%
71. Pharmacokinetics 32%
72. Phenotype 46%
73. Pneumonia 43%
74. Progeria short stature pigmented nevi 87%
75. Prospective Studies 24%
76. Psychiatry 57%
77. Psychology 26%
78. Pulmonary Emphysema 50%
79. Renal Dialysis 48%
80. Risperidone 46%
81. Safety 22%
82. Schizophrenia 31%
83. Single Nucleotide Polymorphism 32%
84. Sleep 18%
85. Small Cell Carcinoma 31%
86. Small Cell Lung Carcinoma 53%
87. Smoke 50%
88. Smokers 65%
89. Smoking 19%
90. Statistics 17%
91. Swine 26%
92. Systematic Reviews 28%
93. Therapeutics 34%
94. Tobacco Products 49%
95. Transforming Growth Factors 40%
96. Triazolam 57%
97. Vascular Endothelial Growth Factor A 66%
98. Vascular Endothelial Growth Factor Receptor-1 20%
99. Warfarin 54%
100. zopiclone 60%